Roivant Sciences Ltd. (ROIV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Roivant Sciences Ltd. (ROIV) Healthcare & Pipeline Overview

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company that develops medicines across various therapeutic areas, including oncology, immunology, and rare diseases. Its unique 'Vant' structure allows focused development efforts, positioning it as an innovator in the biotechnology sector with a significant market capitalization.

What Is the Investment Thesis for ROIV?

Key value drivers include the potential for successful clinical trials and regulatory approvals of its various product candidates, particularly in high-demand therapeutic areas like oncology and immunology. The company's 'Vant' structure allows for focused development and efficient capital allocation. With a market capitalization of $29.4B, Roivant's growth catalysts include advancing its pipeline through clinical stages and securing partnerships for commercialization. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's negative profit margin of -6079.9% highlights the high-risk, high-reward nature of biotechnology investments.

Based on FMP financials and quantitative analysis

ROIV Key Highlights

Market capitalization of $29.4B reflects investor confidence in Roivant's pipeline and business model.

• Gross margin of 91.2% indicates strong potential profitability upon successful commercialization of its drug candidates.
• Beta of 1.21 suggests higher volatility compared to the overall market, typical for biotechnology companies.
• The company's focus on diverse therapeutic areas, including oncology, immunology, and rare diseases, mitigates risk by diversifying its pipeline.
• Roivant's innovative 'Vant' structure allows for specialized expertise and efficient capital allocation, enhancing its competitive advantage.

Who Are ROIV's Competitors?

ROIV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ROIV's Key Strengths?

Innovative 'Vant' structure.

• Diverse pipeline of drug candidates.
• Expertise in acquiring and de-risking drug candidates.
• Strong gross margin potential (91.2%).

What Are ROIV's Weaknesses?

Negative profit margin (-6079.9%).

• High R&D costs associated with drug development.
• Dependence on successful clinical trials and regulatory approvals.
• Limited commercialized products.

What Could Drive ROIV Stock Higher?

Clinical trial results for key drug candidates in oncology and immunology.

• Regulatory submissions and approvals for new therapies.
• Strategic partnerships and collaborations to expand pipeline and market reach.
• Advancement of clinical pipeline through clinical trials.
• Expansion into new therapeutic areas and geographic markets.

What Are the Key Risks for ROIV?

Negative return on equity (-6.9%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $295.7M recently.
• Clinical trial failures for key drug candidates.
• Regulatory hurdles and delays in approvals.
• Competition from established pharmaceutical companies.
• High R&D costs associated with drug development.
• Dependence on successful commercialization of approved drugs.

What Are the Growth Opportunities for ROIV?

• Expansion into New Therapeutic Areas: Roivant has the opportunity to expand its pipeline by acquiring and developing drug candidates in additional therapeutic areas with unmet medical needs. This includes exploring opportunities in areas such as neurology, cardiovascular disease, and metabolic disorders. The global market for these therapeutic areas is estimated to be worth billions of dollars, providing significant growth potential for Roivant. Timeline: Ongoing.
• Strategic Partnerships and Collaborations: Roivant can leverage strategic partnerships and collaborations with other pharmaceutical companies, biotechnology firms, and academic institutions to accelerate the development and commercialization of its drug candidates. These partnerships can provide access to additional resources, expertise, and funding. The market for pharmaceutical collaborations is growing, with increasing demand for innovative therapies and technologies. Timeline: Ongoing.
• Advancement of Clinical Pipeline: Roivant's growth is heavily dependent on the successful advancement of its clinical pipeline through clinical trials and regulatory approvals. Positive clinical trial results and regulatory approvals for its key drug candidates will drive significant value creation for the company. The market for successful drug candidates is substantial, with the potential for blockbuster sales. Timeline: Ongoing.
• Application of Technology to Improve Clinical Trials: Roivant can leverage its expertise in healthcare technology to improve the efficiency and effectiveness of clinical trials. This includes using data analytics, artificial intelligence, and digital health tools to optimize trial design, patient recruitment, and data analysis. The market for clinical trial technology is growing, with increasing demand for innovative solutions to reduce costs and timelines. Timeline: Ongoing.
• Geographic Expansion: Roivant has the opportunity to expand its geographic presence by entering new markets and regions. This includes exploring opportunities in emerging markets with growing healthcare needs and increasing access to medicines. The global market for pharmaceuticals is expanding, with significant growth potential in emerging markets. Timeline: Ongoing.

What Are ROIV's Competitive Advantages?

• Innovative 'Vant' structure allows for focused development and efficient capital allocation.
• Diverse pipeline of drug candidates targeting a wide range of diseases.
• Expertise in acquiring and de-risking promising drug candidates.
• Application of technology to improve clinical trials and data analysis.

What Does ROIV Do?

Roivant Sciences Ltd., founded in 2014 and based in London, is a biopharmaceutical and healthcare technology company dedicated to improving health by rapidly developing innovative medicines and technologies. The company operates through a unique model, launching multiple independent 'Vants,' each focused on specific therapeutic areas or technologies. This decentralized structure allows for specialized expertise and focused development efforts. Roivant's portfolio includes product candidates targeting a wide range of diseases, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company's approach involves acquiring promising drug candidates, de-risking their development, and accelerating their path to market. Roivant's commitment to innovation extends beyond drug development to include the application of technology to improve clinical trials, data analysis, and patient outcomes. With a global presence and a team of over 900 employees, Roivant Sciences continues to expand its pipeline and advance its mission of transforming healthcare.

What Products and Services Does ROIV Offer?

• Researches and develops medicines for various therapeutic areas.
• Launches independent 'Vants' focused on specific diseases or technologies.
• Acquires promising drug candidates and de-risks their development.
• Accelerates the path to market for innovative medicines.
• Applies technology to improve clinical trials and data analysis.
• Develops product candidates for oncology, immunology, and rare diseases.
• Targets diseases such as solid tumors, sickle cell diseases, and psoriasis.

How Does ROIV Make Money?

• Acquires promising drug candidates from other companies or research institutions.
• Develops and de-risks these drug candidates through clinical trials.
• Launches independent 'Vants' to focus on specific therapeutic areas.
• Seeks regulatory approval for its drug candidates.
• Commercializes and markets approved drugs, either independently or through partnerships.

What Industry Does ROIV Operate In?

Roivant Sciences operates within the dynamic and competitive biotechnology industry, characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The industry is driven by the increasing demand for novel therapies to address unmet medical needs. Roivant's unique 'Vant' model and focus on acquiring and developing promising drug candidates position it as a disruptor in the traditional pharmaceutical landscape. The company competes with established pharmaceutical giants and other biotechnology firms, including Revolution Medicines, Inc. (RVMD), Royalty Pharma plc (RPRX), Exact Sciences Corporation (EXAS), Moderna, Inc. (MRNA), and Ascendis Pharma A/S (ASND). The biotechnology industry is projected to continue its growth trajectory, fueled by advancements in genomics, personalized medicine, and biomanufacturing.

Who Are ROIV's Key Customers?

• Patients suffering from various diseases.
• Healthcare providers who prescribe Roivant's medicines.
• Hospitals and clinics that administer Roivant's therapies.
• Pharmaceutical companies that partner with Roivant.

Company Profile

Roivant Sciences Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Matthew Gline. ROIV has traded publicly since 2020.

Return on equity for Roivant Sciences Ltd. stands at -6.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.2%, the inverse of the P/E and a quick read on earnings relative to price.

ROIV Valuation & Market Position

With a $29.4B market cap, Roivant Sciences Ltd. sits in the large-cap segment of the market. Analyst price targets span from $36.00 to $52.00, with a consensus of $43.00. At the current price of $40.66, that implies approximately 6% upside potential. Relative to its peer group, ROIV's quantitative score of 26/100 is below the peer average of 76/100.

Quarterly Financial Performance: Roivant Sciences Ltd.

Revenue for Roivant Sciences Ltd. came in at $1.4M during Q1 FY2026, a 42.8% contraction versus the preceding quarter. The company recorded a net loss of $189.8M, with diluted EPS of $-0.26. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, ROIV averaged $-0.11 in diluted EPS.

Roivant Sciences Ltd.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 47.71 places it in the safe zone, indicating low near-term bankruptcy risk.

Roivant Sciences Ltd. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.9% above estimates on average.

Wall Street analysts project Roivant Sciences Ltd. revenue of about $52.8M for fiscal 2027, with EPS near $-1.39. The estimate reflects 8 contributing analysts.

Over the past six months, Roivant Sciences Ltd. insiders filed 100 SEC Form 4 transactions — 72 sales and 28 purchases. On net that is roughly 12.5M shares disposed (about $295.7M), a signal worth weighing alongside the fundamentals.

ROIV Financials

ROIV Latest News

ROIV Analyst Consensus

ROIV MoonshotScore

Common Questions About ROIV (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources